Companies

Venus Remedies gets patent for Potentox from Mexico

PTI Chandigarh | Updated on March 12, 2018

The global market for treating hospital-acquired bacterial infections was estimated to be worth $9 billion in 2010.

Venus Remedies Limited, a research-based global pharmaceutical company, has received patent from Mexico for its novel antibiotic product Potentox.

Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, a company release said here today.

It said the patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.

Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.

On the response to the product, the release quoting Dheeraj Aggarwal, Chief Financial Officer, Venus Remedies Ltd, said, “The product is growing at a compound annual growth rate (CAGR) of 50 per cent since the past three years.

“To take this novel antibiotic adjuvant entity to Mexico, the company is already holding talks with some big pharmaceutical companies there for strategic tie-ups.

“The common technical document (CTD) for Mexico is ready, and we will soon be filing it. But it will take us another two-three years to launch the product in this market”.

The global market for treating hospital-acquired bacterial infections was estimated to be worth $9 billion in 2010.

Potentox is designed to address the needs of almost 50 per cent of this market, the release said, adding the hospital-treated infections (HTI) market is projected to grow at a rate of 2.7 per cent annually in major economies.

Published on June 17, 2013

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

null
This article is closed for comments.
Please Email the Editor